Hey Folks,
Here are some reasons to keep an eye on Sunshine Biopharma, Inc. (Nasdaq: SBFM)...
1. Twelve more launches are expected this year: The company anticipates bringing 12 additional drugs to market during the remainder of 2026, with another 10 behind them in the pipeline.
2. The target market is doubling: Canada's generic pharmaceuticals market was worth roughly $10.4 billion in 2024 and is projected to reach $19.7 billion by 2033, according to IMARC Group.
3. Generics dominate Canadian prescriptions: More than 70% of prescribed medicines in the country are generics, so this is a core segment of healthcare rather than a niche.
4. It has a fast route to market: Cross-licensing lets Nora Pharma get approval in roughly 45 to 60 days rather than the 12 months a fresh dossier filing requires.
5. The company claims peer-leading growth: Nora Pharma is a relative newcomer among 35-plus competitors but states it has posted one of the fastest year-over-year sales growth rates in the group.
6. An mRNA cancer program sits on top of that: K1.1 is testing whether mRNA — the same class of molecule behind the COVID vaccines — can attack cancer cells directly.
Anyways...
That's all for now!
Until Next Time,
-ZT Team
|